 Even as many big drug makers abandon a once-hot gene technology, a small pocket of companies is doubling down on it, convinced the approach still has promise.. The technology seeks to disable molecules called ribonucleic acids, or RNA, from translating genetic code into disease-causing proteins. As recently as 2010, nearly every large pharmaceutical company, including Pfizer Inc. and Merck & Co., had research teams working on RNA-targeted therapies, but technical challenges in delivering the drugs into human cells led...
  